AOD9604 (Anti-Obesity Drug 9604) is a 16-amino acid synthetic peptide developed in the laboratory of Professor Frank Ng at Monash University in Melbourne, Australia. It corresponds to amino acids 176–191 of the human growth hormone (hGH) sequence, with a tyrosine substitution at the N-terminus to improve stability. The compound was designed to isolate the lipolytic properties of full-length hGH without reproducing its anabolic, diabetogenic, or IGF-1-elevating activity.

The primary body of preclinical work has focused on adipose tissue metabolism, fat oxidation, and beta-adrenergic signaling in rodent obesity models. Research led by Ng and colleagues at Monash University, and later extended by Heffernan and co-investigators, examined lipid metabolism in obese Zucker rats and genetically modified beta₃-adrenergic receptor knock-out mice. A separate line of research examined AOD9604 in cartilage biology models including intra-articular administration. All findings referenced here derive from preclinical models and have not been validated in controlled human clinical trials.

AOD9604 appears in indexed journals including Endocrinology and Annals of Clinical and Laboratory Science. It is not approved by the U.S. Food and Drug Administration for any diagnostic, therapeutic, or preventive application. It is classified as a research compound only.